Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessing the Effect of Contraception and the Menstrual Cycle on Pharmacokinetics, Pharmacodynamics, and Vaginal Safety in Tenofovir Vaginal Gel Users

Next Previous
Trial Profile

Assessing the Effect of Contraception and the Menstrual Cycle on Pharmacokinetics, Pharmacodynamics, and Vaginal Safety in Tenofovir Vaginal Gel Users

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Aug 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tenofovir (Primary) ; Ethinylestradiol/levonorgestrel; Medroxyprogesterone
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors CONRAD

Most Recent Events

  • 11 Sep 2018 Results published in the JAIDS
  • 09 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 11 Dec 2013 Planned end date changed from 1 Oct 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top